Ulcerative Colitis Treatment Reduces Need for Surgery by Almost Half
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Ulcerative Colitis Treatment Reduces Need for Surgery by Almost Half

ROCHESTER, Minn -- October 2, 2009 -- A study published in the October 2009 issue of the journal Gastroenterology has found that ulcerative colitis patients have a 41% reduction in colectomy after 1 year when treated with infliximab.

“Our purpose in this study was to see if the use of infliximab for ulcerative colitis would reduce the need for surgery,” said lead author William Sandborn, MD, Mayo Clinic, Rochester, Minnesota. “We found that treatment with infliximab reduced the need for colectomy by 41% compared with patients treated with placebo.”

The multicentre, international study included 728 patients who received placebo or infliximab 5 or 10 mg/kg for 46 weeks. Patients were monitored for hospitalisation or surgical outcomes.

Of the patients, 87% (630) had complete follow-up for the endpoint of whether or not they had colectomy, while the remaining 13% (98) of patients had follow-up for less then a year, with a median follow-up of 6.2 months.

The research showed that treatment with infliximab at 0, 2, and 6 and then every 8 weeks reduced the incidence of colectomy through 54 weeks by 41% in outpatients with moderate to severe active ulcerative colitis.

The cumulative incidence of colectomy through 54 weeks was 10% for infliximab and 17% for placebo (P = .02). Compared with placebo, fewer ulcerative colitis-related hospitalisations and surgeries/procedures occurred with infliximab therapy.

“One of the most feared outcomes for ulcerative colitis patients is surgical removal of the colon,” says Dr. Sandborn. “Our research hopes to provide other treatment solutions for patients beyond surgery.”

Previous research has shown that infliximab therapy induced clinical remission and bowel healing for colitis patients. This new research provides more information and options for patients struggling with this difficult disease, explains Dr. Sandborn.

SOURCE: Mayo Clinic

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities